In the News Archive
- 2014-04-04 - Sunesis Announces MD Anderson Sponsored Trial of Vosaroxin in AML and High-Risk MDS Poster to be Presented at AACR 2014
- 2014-04-04 - Diffuse large B-cell lymphoma: New guidelines include MYC
- 2014-04-02 - Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia
- 2014-04-02 - Investigation Report on China Imatinib Market, 2009-2018
- 2014-04-02 - Entinostat plus azacitidine may not improve response for myelodysplastic syndrome
- 2014-03-26 - Non-Hodgkin's Lymphoma Center Posts New Study for Effective Treatment of B-cell Non-Hodgkin's Lymphoma
- 2014-03-26 - “Sticky” CML Cells Could Mediate Resistance to Treatment
- 2014-03-24 - Research Finds First-Line Therapy Response Linked to Non-Hodgkin's Lymphoma Survival, According to the Non-Hodgkin's Lymphoma Center
- 2014-03-17 - Ibrutinib Represents “Transformative” Approach in CLL Treatment
- 2014-03-17 - Study Finds New Chemo Combo May be Better for Some Non-Hodgkin’s Lymphomas, According to the Non-Hodgkin’s Lymphoma Center
- 2014-03-17 - New first-line option for follicular lymphoma explored
- 2014-03-10 - Subcutaneous rituximab noninferior to IV formulation in follicular lymphoma
- 2014-03-10 - UVA Researchers Discover Cause of an Aggressive Leukemia
- 2014-03-10 - Researchers Say New Drugs Can Reduce Cardiac Side Effects in Frail Non-Hodgkin’s Lymphoma Patients, According to the Non-Hodgkin’s Lymphoma Center
- 2014-03-10 - Early dasatinib response predicted long-term survival in imatinib-resistant chronic phase chronic myeloid leukemia